Solid Tumor trials recruiting in Ohio

All Solid Tumor trials nationally

Cities in Ohio

Recruiting trials in Ohio

• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
  NCT04300556 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati, Hilliard
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
  NCT07094204 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Dabrafenib and/or Trametinib Rollover Study
  NCT03340506 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Ohio: Columbus
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
  NCT06669117 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Canton
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
  NCT05735080 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Canton
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  NCT05786924 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• SMP-3124LP in Adults With Advanced Solid Tumors
  NCT06526819 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
  NCT06425926 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cincinnati
• Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
  NCT06810544 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland
• Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
  NCT07165132 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Columbus
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Ohio: Cleveland